Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2067208 | Cell Biology International | 2009 | 10 Pages |
Abstract
The biochemical effects of 2-(ethoxymethylthio)-9-phenyl-cyclohepta[d]pyrimidone (EPCP), a novel non-nucleoside reverse transcriptase inhibitor, have been investigated. Treatment with EPCP (EC50 of 0.88Â nM in CEM x174 cells) significantly inhibited the activity of SIV reverse transcriptase and elevated the percentage of viable cells in an SIV-infected sample in a dose-dependent manner. The percentage of cells accumulated in G1 phase increased significantly from 34.5 to 62.4%, with a concomitant reduction in S-phase from 50.7% in the control to 22.6% in the infected group. This cell cycle profile was restored by treatment with EPCP. SIV upregulated the levels of the caspase-3, p53 and bax proteins, and downregulated the level of bcl-2 in infected cells. The apoptotic effect of SIV was also blocked by treatment with EPCP. The pharmacological effects of EPCP paralleled those of AZT, suggesting the possibility that EPCP might be a novel antiviral agent for SIV.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biophysics
Authors
Libo Gao, Shigan Fu, Hui Li, Xiaowei Wang, Junyi Liu, Han Liu, Liyuan Guo, Xinhua Liu, Mengsen Li, Michael A. McNutt, Gang Li,